---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-055407"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:29:56.854733+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incannex achieves database lock for RePOSA Phase 2 trial of IHL-42X; top-line results expected July 2025

## Summary
- Database lock achieved June 16, 2025, on schedule; final statistical analysis begins.
- Top-line results from Phase 2 trial of IHL-42X for obstructive sleep apnoea expected July 2025.
- IHL-42X is a first-in-class oral therapy for OSA; no approved oral pharmacological treatment exists.
- Trial evaluates IHL-42X in moderate to severe OSA patients unable/unwilling to use CPAP.
- Over 900 million people affected by OSA worldwide; IHL-42X aims to address underserved patient population.

## SEC filing metadata
- accession: 0001213900-25-055407
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025055407/0001213900-25-055407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025055407/ea0245975-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-055407
- JSON: https://secwatch.observer/filing/0001213900-25-055407.json
- Plain text: https://secwatch.observer/filing/0001213900-25-055407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.